Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin Zhang

Showing results (291-300 of 373) with videos related to

Pageof 38
Sort By:
Huan Jing Ke Xue= Huanjing Kexue|December 4, 2024
[Characteristics and Source Apportionment of Ambient Volatile Organic Compounds in Shijiazhuang High-tech Industrial Development Zone in Autumn]Xiao Zhang, Ning Zhang, Rui Wei, et al.
Future Oncology (London, England)|July 21, 2025
Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutationXi Chen, Lei Ji, Ying Fan, et al.
International Journal of Cancer|February 4, 2018
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han populationBo Lan, Fei Ma, Xiaoyu Zhai, et al.
Frontiers in Oncology|October 24, 2022
Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapyXiaoyan Qian, Meng Xiu, Qing Li, et al.
The Journal of Clinical Endocrinology and Metabolism|October 2, 2015
Chenodeoxycholic Acid as a Potential Prognostic Marker for Roux-en-Y Gastric Bypass in Chinese Obese PatientsHaoyong Yu, Yan Ni, Yuqian Bao, et al.
Thoracic Cancer|June 13, 2018
Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitorJiayu Wang, Yiqun Han, Xiuqing Shi, et al.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES studyTao Wang, Pin Zhang, Lijun Di, et al.
Therapeutic Advances in Medical Oncology|November 18, 2024
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world studyYujing Tan, Zexi Peng, Hanfang Jiang, et al.
Oncotarget|July 23, 2016
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialPin Zhang, Yi Yin, Hongnan Mo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 19, 2010
A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in miceQi Gao, Yang Jiang, Tian Ma, et al.
Pageof 38

Showing results (291-300 of 373) with videos related to

Sort By:
Pageof 38
Huan Jing Ke Xue= Huanjing Kexue|December 4, 2024
[Characteristics and Source Apportionment of Ambient Volatile Organic Compounds in Shijiazhuang High-tech Industrial Development Zone in Autumn]Xiao Zhang, Ning Zhang, Rui Wei, et al.
Future Oncology (London, England)|July 21, 2025
Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutationXi Chen, Lei Ji, Ying Fan, et al.
International Journal of Cancer|February 4, 2018
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han populationBo Lan, Fei Ma, Xiaoyu Zhai, et al.
Frontiers in Oncology|October 24, 2022
Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapyXiaoyan Qian, Meng Xiu, Qing Li, et al.
The Journal of Clinical Endocrinology and Metabolism|October 2, 2015
Chenodeoxycholic Acid as a Potential Prognostic Marker for Roux-en-Y Gastric Bypass in Chinese Obese PatientsHaoyong Yu, Yan Ni, Yuqian Bao, et al.
Thoracic Cancer|June 13, 2018
Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitorJiayu Wang, Yiqun Han, Xiuqing Shi, et al.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES studyTao Wang, Pin Zhang, Lijun Di, et al.
Therapeutic Advances in Medical Oncology|November 18, 2024
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world studyYujing Tan, Zexi Peng, Hanfang Jiang, et al.
Oncotarget|July 23, 2016
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialPin Zhang, Yi Yin, Hongnan Mo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 19, 2010
A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in miceQi Gao, Yang Jiang, Tian Ma, et al.
Pageof 38